companydata.dkNovo Nordisk Invest 4 A/S: Financial statements 2022
CVR: 31853923
Novo Nordisk Invest 4 A/S (CVR 31853923) has filed annual accounts for 2022. In 2022, the company reported a gross profit of DKK -6,000 and a net result of DKK 4,000 compared with DKK -37,000 the year before. Equity amounted to DKK 1,783,000. The solvency ratio was 90.2%.
- Gross Profit
- -6,000 kr.
- Profit/Loss
- 4,000 kr.
- Equity
- 1,783,000 kr.
- Total Assets
- 1,977,000 kr.
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2022 | - | -6 t. | 4 t. | 1.8 mio. | - |
| 2021 | - | - | -37 t. | 1.8 mio. | - |
| 2020 | - | - | -108 t. | 1.8 mio. | - |
| 2019 | - | - | -398 t. | 8.9 mio. | - |
| 2018 | - | - | 189 t. | 9.3 mio. | - |
Keep an eye on Novo Nordisk Invest 4 A/S
Get notified instantly about new financial statements, ownership changes, management changes and status changes.
Set up monitoringEvents in 2022
Novo Nordisk Invest 4 A/S has published its annual report for 2021. The net result was DKK -37,000.
About Novo Nordisk Invest 4 A/S
Novo Nordisk Invest 4 A/S is a Danish company of the type Aktieselskab based in Bagsværd, founded in 2008. The company is registered under the industry Ikke-finansielle holdingselskaber. The company was previously named STENO DIABETES CENTER A/S. The management consists of Anders Rytter Mikkelsen. The company is owned by NOVO NORDISK A/S. The company has 0 employees. In 2025, the company reported a gross profit of DKK -64,000 and a net result of DKK -23,000 compared with DKK 7,000 the year before. Equity amounted to DKK 1,772,000.